Binger Strasse 173
55216 Ingelheim am Rhein
Ingelheim, Germany, 30 August 2012 – Boehringer Ingelheim has announced the European approval for its latest innovation in Animal Health: the MycoFLEX® Headspace bottle, a simple and practical way to mix the two pig vaccines Ingelvac CircoFLEX® and Ingelvac MycoFLEX® for their simultaneous application. The headspace design – originally inspired by customer demand – allows the two vaccines to be mixed directly in the Ingelvac MycoFLEX® bottle, thus eliminating the need for an additional mixing vessel.
Based on a European wide market research as much as 83 % of veterinarians who vaccinate their pigs against PCV2 (Porcine Circovirus type 2) and M. hyo (Mycoplasma hyopneumoniae) are mixing both vaccines.1 This provides several benefits in animal welfare (less stress for pigs through single-shot injection of the vaccine mix), farm economics (saving labour) and animal health (fewer chances for pathogen transfer via injection needles). The FLEXcombo® concept of the mixable stand alone vaccines is the first and only solution to protect pigs both against PCV2 and M.hyo with a single shot.
Ingelvac CircoFLEX® is established globally as customers’ number one choice for PCV2-vaccination while Ingelvac MycoFLEX® is the market leader in several countries, including USA, Germany, Denmark, Sweden, The Netherlands, Belgium, Italy, Poland, Czech Republic, Hungary, Mexico, Taiwan and South Korea.2
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
1. MES market research “Produkt+Markt” Germany, Denmark, Spain, France, Netherlands, UK, Italy, Belgium, 2011 (data on file).
2. Based on 2011 local and international market research data (data on file).